ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AGL Angle Plc

14.00
0.25 (1.82%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.25 1.82% 14.00 13.50 14.50 14.00 13.75 13.75 659,855 09:11:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Business Services, Nec 1.04M -21.69M -0.0832 -1.68 36.48M
Angle Plc is listed in the Business Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 13.75p. Over the last year, Angle shares have traded in a share price range of 9.125p to 37.50p.

Angle currently has 260,580,547 shares in issue. The market capitalisation of Angle is £36.48 million. Angle has a price to earnings ratio (PE ratio) of -1.68.

Angle Share Discussion Threads

Showing 23326 to 23348 of 32775 messages
Chat Pages: Latest  939  938  937  936  935  934  933  932  931  930  929  928  Older
DateSubjectAuthorDiscuss
26/1/2023
11:30
I hope you're right but proof of the pudding etc.....at least he speaks American and is in the right country/time zone/market arena......
fevertreeman
26/1/2023
11:27
THe share price will be what the share price will be and of course inflows and outflows move it. What's important and ultimately what makes the stock market a weighing rather than counting machine, is the underlying INVESTMENT CASE. i.e. what's the sector, what's the market opportunity, whats the strategy, can management execute, what do the numbers look like.................so Newland's job has been to show that he has a GRIP on all the above. What the share price reaction since May indicates that the MARKET believes that NEWLAND DOES NOT HAVE A GRIP and unless, and until, that changes it seems pointless to me to look at charts, and coiled springs, and new investors etc....
fevertreeman
26/1/2023
11:25
Let's see what difference Joe Eid makes over the next few months. He has top 10 pharma experience:Joe most recently served as Chief Medical Officer and Head of Global Drug Development for Princeton, New Jersey based Luzsana Biotechnology (a wholly owned subsidiary of Jiangsu Hengrui Pharmaceutical). Importantly, his previous experience includes senior positions in clinical development and medical affairs at Bristol Myers Squibb, Merck & Co. and Hoffman-La Roche.
parob
26/1/2023
11:22
Dnl dddd and agl You wouldnt wish those boards on anyone !!!
s34icknote
26/1/2023
11:17
My mention of BG was shorthand for all investors. SELVEY is in my view HUGELY culpable for the fiasco. Asleep a the wheel doesn't begin to sum up his chairmanship -he has been a the helm for far too long. The Board is all over the palce, 2 NEDs in rapid succession smacks of panic. Selvbery should step down asap and hand ove rto someone with current medtech/pharma corproate exeprience and a ruthless commercial focus who isnt going to be brow-beaten or given teh runaround by NEWLAND
fevertreeman
26/1/2023
11:11
In 60 years of investing I have never been invested in a share whose price changes irritated me so much!

Being 75 years old I just hope that I will live long enough to see Parsortix benefit patients in the ways I anticipated.

clausentum
26/1/2023
11:07
U really don't get what's happened or happening here....This is the ungovernable AIM market !
amaretto1
26/1/2023
10:59
Investor relations ..... your job !! We have a spurious seller ??It's your job to rest assure holders investors ......i say spurious.... because the lack of TR1s leads me to believe.... the whole recent RNS was a Hatchet job ...To swap Argon position in to a hedge fund hands... simultaneously being shorted heavily down .... at the expense of margined private investors!
amaretto1
26/1/2023
10:56
There really can't be many low/mid 20s buyers left to clear now. Those that wanted out have had plenty of time to sell. Hopefully this is the last dip before a move up, and of course we have the prospect of CLSC buying in from next Wed should their IPO be successful. I'll be keeping an eye on volumes.
parob
26/1/2023
10:54
FTM. wholeheartedly agree , but it is ALL investors who deserve an explanation of why the crash AND more importantly right now exactly what is being progressed to retrieve this complete fiasco. From memory AN was talking £10 post FDA , what is his current forecast and by when ????
millwallfan
26/1/2023
10:15
And why have you not approached illumina .... knowing they have just bought Grail for 7 billion ???
amaretto1
26/1/2023
10:09
How can their be a slow down across the board ??Do people stop getting cancer ? Andrew Newland has been a HUGE disappointment to private investors... the share price is telling you all this. Is he letting in his hedge fund mates ?? Who knows .... the valuation of the IP is completely bizzare compared to sector ..... i suggest far far more pressure being put on AGL telephone Guildford today.
amaretto1
26/1/2023
10:03
I was very pleased with the commercial performance of Angle plc following fda.

if you read the recent update there has been a slowdown across the board not just Angle plc.

joinednow
26/1/2023
09:58
Perhaps the most depressing feature of the sags to date is just ill-prepared Newland and his board were ahead of FDA approval. It's as if the approval caught them by surprise. I don't buy the argument that the share price reaction is simialr to other small caps, not that the market conditions are against Angle. Newland has had a decade to get the company into a position to ensure that there was (1) detailed commercial strategy once approved that had been properly road-tested (2) Board of Directors that were fit for purpose (3) Management bench strengthened.

The reversals since FDA approval are shocking frankly. Baillie GIfford and other investors who supported Newland's equity raise are fully entitled to demand an explanation from Selvey and Newland about the course of event since May. The longer Newland is unablew to provide serious proper newsflow the more difficult things get within a small listed R&D driven company like this (I know I worked for one).

This type of company is chock full of bright people with multiple degrees who can't be brushed off as easily as investors. It doesnt take a crystal ball or any great knowledge of how small research driven business work to assume internal morale must be through the floor leading to (1) a serious risk of brain drain of key people (2) staff disaffection (3) CEO & CFO credibility damaged.

fevertreeman
26/1/2023
08:54
That's probably what GFI are thinking. Their holding in Amryt Pharma doubled in value when they were bought out recently.
parob
26/1/2023
08:51
Wonder if there is any chance of Abbott (market cap $ 200 billion dollars!) acquiring Angle for their technology ?
kimchi1
26/1/2023
08:42
As well as 'collaboration' with Abbott, whatever happened with the work with Philips and Quinetics from 2017?
fhmktg
25/1/2023
16:45
There are charity directors on more.
niaroo
25/1/2023
16:43
But their share price is going up.
eeza
25/1/2023
16:39
No a lot worse !!They have at least one director on 500k PA ......
amaretto1
25/1/2023
16:38
Genedrive isn't saddled with Newland the Gob.
eeza
25/1/2023
16:34
U got a beef with PATT .... stick to PATT ....But don't ever try including me in this !!! Believe me
amaretto1
25/1/2023
16:32
£100 million . Thats why there are so many aim companies. A lot of rich directors using other peoples money. A bit like most charity directors.
niaroo
Chat Pages: Latest  939  938  937  936  935  934  933  932  931  930  929  928  Older

Your Recent History

Delayed Upgrade Clock